

Alexander Reinhaller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5843875/publications.pdf>

Version: 2024-02-01

69
papers

3,751
citations

394421

19
h-index

133252

59
g-index

71
all docs

71
docs citations

71
times ranked

4594
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
2	Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2011, 100, 116-123.	0.6	649
3	Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. <i>Radiotherapy and Oncology</i> , 2007, 83, 148-155.	0.6	475
4	Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. <i>Gynecologic Oncology</i> , 2015, 138, 560-565.	1.4	125
5	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 512-517.	1.4	124
6	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR) Tj ETQq0 0,0 rgBT /Overlock 10	2.5	108
7	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	10.7	104
8	Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. <i>BMC Cancer</i> , 2010, 10, 666.	2.6	96
9	Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0140403.	2.5	92
10	C-reactive protein is a prognostic parameter in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, 114-117.	1.4	72
11	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients " A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110.	2.8	53
12	The Inflammation-Based Glasgow Prognostic Score Predicts Survival in Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1052-1057.	2.5	44
13	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	1.8	42
14	Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 74.	2.4	33
15	Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1667-1671.	2.5	33
16	Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1664-1671.	2.5	32
17	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015, 136, 37-42.	1.4	29
18	The prognostic role of metformin in patients with endometrial cancer: a retrospective study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 203, 291-296.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1056-1065.	2.0	20
20	Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1015-1022.	1.7	20
21	Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019, 153, 286-291.	1.4	20
22	Prognostic value of serum creatine level in patients with vulvar cancer. <i>Scientific Reports</i> , 2019, 9, 11129.	3.3	19
23	Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1055-1062.	1.7	19
24	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 139-143.	0.5	16
25	Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. <i>Cancer Letters</i> , 2019, 459, 1-12.	7.2	16
26	Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial. <i>Gynecologic Oncology</i> , 2022, 165, 23-29.	1.4	16
27	Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma – a multicenter study. <i>Scientific Reports</i> , 2017, 7, 14474.	3.3	14
28	PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. <i>Scientific Reports</i> , 2021, 11, 6400.	3.3	14
29	The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e1.	2.2	14
30	Risk of endometrial cancer in asymptomatic postmenopausal patients with thickened endometrium: data from the FAME-Endo study: an observational register study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 813-820.	1.7	13
31	Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 548.	3.7	13
32	Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 48.	2.5	13
33	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCG and EORTC-GCG study. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	12
34	Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen. <i>PLoS ONE</i> , 2017, 12, e0182383.	2.5	12
35	Effect of Preoperative Warm-up Exercise Before Laparoscopic Gynecological Surgery: A Randomized Trial. <i>Journal of Surgical Education</i> , 2016, 73, 429-432.	2.5	11
36	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	1.8	11

#	ARTICLE	IF	CITATIONS
37	Plasma fibrinogen levels in patients with benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2015, 136, 567-570.	1.4	10
38	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	2.8	10
39	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	3.7	10
40	A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. <i>Gynecologic Oncology</i> , 2018, 149, 140-145.	1.4	9
41	The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 430-440.	2.0	9
42	Low anterior resection syndrome (LARS) in ovarian cancer patients - A multi-centre comparative cohort study. <i>International Journal of Surgery</i> , 2020, 78, 97-102.	2.7	9
43	AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 123-127.	1.7	8
44	Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses. <i>Gynecologic Oncology</i> , 2017, 147, 690-694.	1.4	8
45	Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery. <i>Gynecologic Oncology</i> , 2019, 154, 577-582.	1.4	8
46	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573.	5.1	7
47	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIIG and EORTC-GCC study. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	7
48	The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. <i>PLoS ONE</i> , 2015, 10, e0133838.	2.5	7
49	The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study. <i>PLoS ONE</i> , 2017, 12, e0169272.	2.5	7
50	Cervical Adenocarcinoma in Situ: Update and Management. <i>Current Obstetrics and Gynecology Reports</i> , 2013, 2, 86-93.	0.8	6
51	Impact of frailty on the management of patients with gynecological cancer aged 80 years and older. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 557-563.	1.7	6
52	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	2.2	6
53	Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 387-394.	1.1	5
54	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 1076.	3.7	5

#	ARTICLE	IF	CITATIONS
55	A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5080-5080.	1.6	5
56	Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma. <i>Scientific Reports</i> , 2016, 6, 33757.	3.3	4
57	ABO blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study. <i>BMC Cancer</i> , 2018, 18, 447.	2.6	4
58	Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. <i>Oncologist</i> , 2020, 25, e1060-e1069.	3.7	4
59	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5031-5031.	1.6	4
60	Effect of Viewing Disney Movies During Chemotherapy on Self-Reported Quality of Life Among Patients With Gynecologic Cancer. <i>JAMA Network Open</i> , 2020, 3, e204568.	5.9	3
61	The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 59-67.	1.8	3
62	3D MRI-based brachytherapy for cervical cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 351-358.	0.4	2
63	Gamma-glutamyltransferase as a preoperative differential diagnostic marker in patients with adnexal mass. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 239, 16-20.	1.1	2
64	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2
65	PET/MRI in cervical cancer: Insights into tumor biology.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5597-5597.	1.6	1
66	Epithelial ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 143-144.	0.5	0
67	Nomogram prediction for overall survival of patients diagnosed with cervical cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5111-5111.	1.6	0
68	The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16524-e16524.	1.6	0
69	Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.9	0